Robert L. McNeil, Jr. Professor of Translational Research and Professor of Psychiatry, of Neuroscience, and of Psychology; Co-Director, Yale Center for Clinical Investigation; Chair, Psychiatry; Physician-in-Chief of Psychiatry, Yale New Haven Hospital; Director: NIAAA Center for the Translational Neuroscience of Alcoholism; Director, Clinical Neuroscience Division, VA National Center for PTSD
- Alcoholism
- Drug Therapy
- Genetics
- Neurobiology
- Psychiatry
- Schizophrenia
- Stress Disorders, Post-Traumatic
- Veterans
- Neuroimaging
Dr. Krystal is a leading expert on the neurobiology and treatment of psychiatric disorders. His work links psychopharmacology, neuroimaging, molecular genetics, and computational neuroscience to study the neurobiology and treatment of disorders including alcohol use disorder, depression, PTSD, and schizophrenia. He is best known for leading the discovery of the rapid antidepressant effects of ketamine in depressed patients. Within Yale, he chairs the Department of Psychiatry, serves as Chief of Psychiatry for the Yale-New Haven Health System, co-leads the Yale Center for Clinical Investigation (CTSA), co-directs the NIAAA Center for the Translational Neuroscience of Alcohol, and leads the Clinical Neuroscience Division of the National Center for PTSD (VA). In addition to his roles at Yale, he serves as editor of Biological Psychiatry, Vice-President of the Scientific Council for the Brain and Behavior Research Foundation, as a Scientific Advisory Board member of Aligning Research to Impact Autism, and in numerous other advisory capacities for government agencies, academia initiatives, private foundations, and pharmaceutical/biotechnology companies. He also co-founded Freedom Biosciences, a company devoted to addressing the limitations of current rapid-acting antidepressants. Dr. Krystal previously co-chaired (2018-2024) the Forum on Neuroscience and Nervous System Disorders of the National Academies of Sciences, Engineering, and Medicine. He also served on the Department of Defense Psychological Health Advisory Committee, the National Advisory Councils for the National Institute of Mental Health and the National Institute on Alcohol Abuse and Alcoholism, and the NIMH Board of Scientific Counselors (chair, 2005-2007). He has led the American College of Neuropsychopharmacology (president, 2012), and International College of Neuropsychophamacology (president, 2016-2018).